Rega Institute for Medical Research, Department of Microbiology and Immunology, University of Leuven, Leuven, Belgium.
Department of Gastroenterology, Hepatology and Endocrinology, Center of Internal Medicine, Hannover Medical School, Hannover, Germany.
Gastroenterology. 2014 Nov;147(5):1008-11.e7; quiz e15-6. doi: 10.1053/j.gastro.2014.08.040. Epub 2014 Aug 30.
We analyzed blood samples collected from 15 patients with chronic hepatitis E who were recipients of solid-organ transplants. All patients cleared the hepatitis E virus (HEV) except for 2 (nonresponders); 1 patient died. A G1634R mutation in viral polymerase was detected in the HEV RNA of the nonresponders; this mutation did not provide the virus with resistance to ribavirin in vitro. However, the mutant form of a subgenomic replicon of genotype 3 HEV replicated more efficiently in vitro than HEV without this mutation, and the same was true for infectious virus, including in competition assays. Similar results were obtained for genotype 1 HEV. The G1634R mutation therefore appears to increase the replicative capacity of HEV in the human liver and hence reduce the efficacy of ribavirin.
我们分析了 15 例慢性戊型肝炎接受实体器官移植患者的血液样本。除了 2 例(无应答者)外,所有患者均清除了戊型肝炎病毒(HEV);1 例患者死亡。在无应答者的 HEV RNA 中检测到病毒聚合酶的 G1634R 突变;该突变并未使病毒在体外对利巴韦林产生耐药性。然而,3 型 HEV 的亚基因组复制子的突变形式在体外比没有该突变的 HEV 更有效地复制,包括在竞争测定中也是如此。1 型 HEV 也得到了类似的结果。因此,G1634R 突变似乎增加了 HEV 在人肝中的复制能力,从而降低了利巴韦林的疗效。